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Treatment of age-macular degeneration requires monthly intravitreal injections, which are costly and
have serious risks. The objective of this study was to develop a novel intraocular implant for drug deliv-
ery. The capsule drug ring is a reservoir inserted in the lens capsule during cataract surgery, reﬁllable and
capable of delivering multiple drugs. Avastin was the drug of interest in this study. Prototypes were
manufactured using polymethylmethacrylate sheets as the reservoir material, a semi-permeable mem-
brane for controlled delivery and silicone check valves for reﬁlling. The device showed near-zero order
release kinetics and Avastin stability was investigated with accelerated temperature studies.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Age-related macular degeneration (AMD), the leading cause of
blindness in the US, has two principal forms: ‘‘wet” or exudative
(characterized by angiogenesis or growth of new blood vessels),
and ‘‘dry” or non-exudative (characterized by geographic atrophy
and drusen, and a steady rate of progression to ‘‘wet” disease). In
the US, there are over 2 million people with advanced AMD (ex-
pected to double by 2020), and worldwide, there are 30 million
people with this condition (Geroski & Edelhauser, 2000). While
current anti-angiogenic modalities offer signiﬁcant beneﬁt to
many patients with neovascular AMD, indeﬁnite monthly intravi-
treal injections are costly due to the need for retina specialists,
have serious risks (e.g., retinal detachment, endophthalmitis, hem-
orrhage, and cataractogenesis), and are, understandably, not well-
accepted by patients.
Glaucoma is the leading cause of blindness in the African-Amer-
ican community. It affects 2 million Americans overall (Congdon
et al., 2004; Lee et al., 2007). Current therapy revolves on lowering
eye pressure using topical eyedrops. Patient understanding of and
adherence to complex medical regimens is often poor (Balkrishnan,
Bond, Byerly, Camacho, & Anderson, 2003), frequently resulting in
the need for costly and high-risk surgical drainage procedures,
including trabeculectomy and tube shunt procedures.ll rights reserved.
khia).Various routes of administration may be used for intraocular
drug delivery. These include oral and topical delivery and injec-
tions of various kinds: subconjunctival, sub-tenon, retrobulbar,
intravitreal, and systemic (intravenous). Disease circumstances
and the nature of the drug control the selection of route of admin-
istration. Less than 5% of topically administered pharmaceuticals
reach the anterior chamber, making it almost impossible for them
to reach the posterior segment. Even though the lacrimal turnover
rate is only about 1 ll/min, the excess volume of the instilled ﬂuid
ﬂows to the nasolacrimal duct rapidly in a few minutes (Urtti &
Salminen, 1993). Systemic drug delivery, although it can deliver
drugs to the posterior segment, but often is precluded by systemic
side effects of doses required to overcome blood dilution and the
blood–retinal barrier.
Current intraocular drug delivery devices include the Retisert,
Vitrasert, Ozurdex, Medidur, and Neurotech’s NT-501. All of these
require intravitreal procedures and often suturing. These are single
drug agents targeting chronic uveitis such as ﬂuocinolide – Retisert
and dexamethasone – Posurdex (Brumm & Nguyen, 2007), CMV
retinitis such as ganciclovir – Vitrasert (Koch, Gumbel, Hattenbach,
& Ohrloff, 1999), diabetic macular edema such as Medidur (Grover,
Li, & Chong, 2008), and the dry form of macular degeneration such
as ciliary neurotrophic factor-NT-501 (Sieving et al., 2006). None of
these devices are reﬁllable, nor do they target glaucoma or the wet
(exudative) form of macular degeneration, which are the leading
causes of severe visual loss. There have been a few attempts made
towards reﬁllable ocular drug delivery devices, but all of them
require either active control or sutures and none of them have been
Fig. 2. The schematic diagram showing CDR architecture. The drug reservoir (shell),
silicone valves and semi-permeable membrane are shown in the diagram.
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2002).
We propose a new approach that leverages the frequency of cat-
aract extraction and the space within the lens capsule. Cataract
procedures are the most common surgery (3,000,000 in the US
annually; indeed, clear lens extractions (technically the same pro-
cedure as a cataract extraction) are routinely performed simply to
eliminate the need for glasses or contact lenses). Intraocular lenses
placed at time of surgery leave considerable unﬁlled circumferen-
tial space in the lens capsule. The use of this untapped area is a no-
vel approach for potential drug delivery (Fig. 1). The capsule drug
ring (CDR) is a device designed to be implanted in the peripheral
lens capsule during or after cataract surgery without sutures.
Avastin, the drug of interest in this study has been thoroughly
investigated as a potential alternative anti-angiogenic for treat-
ment of AMD. A recent randomized control trial between Avastin
and Lucentis (the anti-VEGF Fab fragment of Avastin) showed no
difference in early efﬁcacy in treatment of neovascular AMD (Subr-
amanian et al., 2009). Intravitreal injection of bevacizumab (Ava-
stin) had resulted in a signiﬁcant decrease in macular edema
and improvement in visual acuity (Iturralde et al., 2006; Lang,
1995). Intravitreal injection of Avastin for patients with macular
edema due to non-ischemic central retinal vein occlusion (CRVO)
resulted in a signiﬁcant decrease in central retinal thickness
(CRT) (Beutel et al., 2008). Intravitreal injections of bevacizumab
versus triamcinolone acetonide were also compared in prolifera-
tive diabetic retinopathy showing that bevacizumab had the low-
est levels of VEGF and potentially diminishes not only VEGF but
also SDF-1alpha. These ﬁndings suggest that intravitreal bev-
acizumab may inﬂuence intraocular mediators beyond VEGF
(Arimura et al., 2009).
The objectives of the present study were to develop a novel
intraocular device that ﬁts in the lens capsule and to determine
the feasibility of developing a reﬁllable reservoir for sustained drug
release. Speciﬁcally, device characterization with respect to mem-
brane type and pore size, valve bonding and functionality and
in vitro testing of the drug release kinetics (PVA and Avastin con-
centrations) were carried out to estimate the device feasibility.2. Methods
2.1. Materials
Avastin molecular weight approximately 149 kDa (Bevaciz-
umab (Avastin, Genentech, South San Francisco, CA)) is a recom-
binant humanized monoclonal immunoglobulin G1 antibody that
inhibits human vascular endothelial growth factor (VEGF). It is
approved by the United States Food and Drug Administration forFig. 1. The schematic diagram of eye showing CDR location inside lens capsule.intravenous use. Polyvinyl alcohol 87–89% hydrolyzed and mwt
146–186 kDa was purchased from Sigma–Aldrich.
2.2. CDR device fabrication
2.2.1. Assembly
The reservoir shell of the CDR was manufactured by milling
poly methyl methacrylate (PMMA) sheet (Cat. number: ME
303011, Perspex, Goodfellow, Inc., PA) using a CNC machine with
a tolerance of ±0.000500 (±12.5 lm). A ring of 13.0 mm outside
diameter and 9.2 mm inside diameter was made from a Perspex
sheet of 1.0 mm thickness. The wall thickness of the ring was
0.1 mm including the sidewalls and bottom wall. The volume of
the drug reservoir was 50 ll. A 1 mm wide port is conﬁgured on
the inner face of the shell to allow for easy access to the silicone
valves (Part number: HT-6135, Bisco Silicones, IL). The valves are
made from a sheet of 254 lm thick silicone by cutting thin strips
of 1 mm  3 mm using a knife plotter (Part number: FC5100-75,
Graphtec, CA). The valves are attached to the inside edge of the
CDR shell using an epoxy (Part number: Loctite 4011, Henkel
Corporation, CT). The same epoxy was used to bond semi-perme-
able membrane (Part number: VSWP02500, Millipore, MA). The
membrane was cut to appropriate ring size using a customized
coring tool to obtain smooth edges.
2.2.2. Valve competency testing
Valve competency testing was performed via pressure monitor-
ing. The PMMA shell reservoir’s open face was closed by the semi-
permeable membrane. A standard non-coring 27 G cannula was
used to re-enact 12 reﬁlling procedures by inserting the cannula
12 times through the valve. The PVA matrix was injected into the
device using a 3 ml plastic syringe (BD, NJ). An in-line pressure
transducer (Part number: 6069, Utah Medical Products, Inc., UT)
was used to detect leakage which was deﬁned as a reduction in
pressure by 15%. The valve was then considered to be competent
if no change in pressure greater than 15% was detected with this
in-line pressure transducer.
2.3. Membrane permeability assay
The objective of this experiment was to assess the permeability
of Avastin (drug of interest) across various semi-permeable mem-
branes in vitro. This information will help in choosing the semi-
permeable membrane of suitable kinetics to be incorporated in
the device for drug release studies. Experiments were carried out
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with effective diffusion area around 0.8 cm2. Experiments were
carried out with Avastin. The semi-permeable membranes were
sandwiched between the two diffusion half-cells with the edge of
the membrane sealed with paraﬁlm. Cellulose ester (100 nm and
25 nm pore size) and polypropylene (100 nm) were the semi-per-
meable membranes used to construct the membrane systems in
Table 2 in the present study. The membranes are 100 lm in thick-
ness. The diffusion cell was placed in a circulating water bath at
36 ± 1 C. Unless otherwise stated, 2 ml of balanced salt solution
(BSS) and 2 ml donor solution were then pipetted into the receiver
and donor chambers, respectively. The donor solution was pre-
pared by mixing an appropriate amount of Avastin in BSS, typi-
cally in the range of 30–100 lg/ml. Twenty-microliter aliquots
were taken from the donor chamber, and 1 ml samples were with-
drawn from the receiver chamber at predetermined time intervals
(1–5 h depending on membrane). Fresh BSS solution was then
added back to the receiver chamber to maintain a constant volume
in the chamber.
For the purpose of the present study, the free aqueous diffusion
coefﬁcient (D) of Avastin was determined under the assumption
that Avastin has similar frictional coefﬁcient ratio as bovine ser-
um albumin (BSA). The diffusion coefﬁcient of BSA at 20 C in pure
water is 6.1  107 cm2/s (Cantor & Shimmel, 1980). The free aque-
ous diffusion coefﬁcient of Avastin at 37 C could be calculated
using the diffusion coefﬁcient of BSA and correcting for the molec-
ular weight difference and the viscosity of water at 37 C.
DAvastin ¼ DBSA g20 Cg37 C
MBSA
MAvasti
 1=3
ð1Þ
where g20 C is the viscosity of water at 20 C, g37 C the viscosity of
water at 37 C, MBSA the molecular weight of BSA, and MAvastin the
molecular weight of Avastin.Table 1
Summary of infusion pressures for silicone valves punctured with a 27 G needle
(mean ± SE, N = 3).
Number of punctures Infusion pressure (kPa)
Valve 1 Valve 2
1 1 70.4 ± 1.6
12 1 67.73 ± 1.49
12 12 62.28 ± 1.592.4. Drug release experiments
To assess diffusion from the CDR, Avastin was lyophilized and
reconstituted to a concentration of 2 or 4 mg of drug mixed with 50
or 75 mg/ml of polyvinyl alcohol (a stabilizing carrier) in 50 ll of
total volume injected into the CDR. Each CDR was placed in a vial
with 4 ml of BSS solution. The volume 4 ml was chosen to approx-
imate the human vitreous volume. The CDRs used in this studyFig. 3. The picture of a prototype prior to membrane and valvwere the same design as stated in the CDR device section but using
2 mm sheets of PMMA. We believe that the dissolution kinetics
will not be altered by the thickness of the impermeable polypro-
pylene sheets as long as the thickness and area of the semi-perme-
able membrane remains the same. The vials were placed on a
heating pad at 40 C. One milliliter samples were taken at prede-
termined time intervals (approximately 1 day). Fresh BSS was re-
placed to remain a constant volume in the vial.2.5. ELISA for Avastin quantiﬁcation
Brieﬂy, the 165-amino acid variant of human recombinant VEGF
were immobilized on Microlite 2 (Thermo Labsystems, Franklin,
MA). The samples to be assayed were diluted so as to be within
the linear range of the assay. Samples and standard solutions were
diluted in StabilCoat reagent (Surmodics, Inc., Eden Prairie, MN).
The bound bevacizumab was detected with a goat antihuman
IgG/Fc antibody labeled with (HRP) horseradish peroxidase (Jack-
son ImmunoResearch Lab., Inc., PA). The detection of HRP was per-
formed with HRP substrate solution and 1 M H2SO4 for stopping
the reaction. The wells were then transferred to a transparent 96
well plates for color absorbance measurement at 450 nm with cor-
rection at 562 nm.2.6. Accelerated stability testing for (Avastin + PVA)
At supraphysiological temperatures, drug degradation is accel-
erated, allowing us project product shelf life or compare relative
stability of alternative formulations. The Arrhenius equation de-
scribes the relationship between storage temperature and degra-
dation rate. Four vials of Avastin (0.14 mg/ml) + PVA (50 mg/ml)
were prepared. One vial placed in 4 C was served as control. ELISAe assembly with a 27 G cannula in the valve access port.
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placed at 70 C, 60 C, and 50 C. Assuming ﬁrst order kinetics:
lnK ¼ Ea
RT
þ lnA ð2Þ
where K is the rate constant, Ea the activation energy, A the pre-
exponential factor, T the temperature (K), R the gas constant.Table 2
Permeability and diffusion coefﬁcients of Avastin across semi-permeable mem-
branes in vitro (mean ± SE, N = 3).
Avastin permeability coefﬁcient CE 100 nm CE 25 nm PP 100 nm
Permeability coefﬁcient
(107 cm/s)
1.74 ± 0.06 0.99 ± 0.10 11.80 ± 2.33
Fig. 4. Permeability plots for (a) CE 25 nm, (b) CBy plotting ln K versus 1/T one can predict the rate constant at
37 C (body temperature).3. Results
3.1. Fabrication
The CDR shell was fabricated at the U. Utah Department of
Mechanical Engineering workshop facility. An example of such
prototype (without overlaying membrane) with a 27 G cannula
in the valve port is shown in Fig. 3. The CNC machining of the
Perspex sheet allowed us tight control over the geometrical dimen-
sions with less than 2% variability.E 100 nm, and (c) PP 100 nm, respectively.
Fig. 5. Cumulative Avastin amount released versus time.
Fig. 6. Arrhenius plot. The log k values derived in this study are plotted versus
inverse temperature (K).
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One of the challenges with this ‘‘rigid” design of CDR was re-
moval of trapped air as it could limit drug volume or induce excess
pressure on the valve membrane and subsequent difﬁculties in
reﬁlling. To alleviate this problem, both membranes were pre-
punctured with a 27 G cannula to allow easy escape for the trapped
air. The CDR prototypes were loaded with 50 mg/ml PVA solution
with simultaneous recording of the infusion pressure using an in-
line pressure transducer. The infusion pressure applied manually
was increased until PVA leakage was observed. The same experi-
ment was reported for multiple membrane punctures to ensure
mechanical integrity of the valves over long durations of utility.
The infusion pressures for 50 ll PVA injected are listed in the Table
1. In each of the experiments, no leakage was found from either
valves or membrane interface after PVA injections. It should be
noted that the infusion time required to completely ﬁll the reser-
voir was less than 1 min.
3.3. Membrane permeability assay
Table 2 shows the permeability coefﬁcient results for Avastin
across the semi-permeable membranes. The hydrophilic CE mem-
brane was superior to the hydrophobic polypropylene (PP), likely
due to the hydrophobic nature of PP that could interact with Ava-
stin. Fig. 4 shows the cumulative amount of Avastin transported
in the receiver versus time for the three different membranes
tested. The PP membrane showed a lag time between 3 and 6 h
(n = 3) with a high and undesirable permeability coefﬁcient. The
three sets of data were statistically signiﬁcant with p < 0.05. The
cellulose ester membrane of 100 nm provided a higher permeabil-
ity coefﬁcient (2 times) than 25 nm as expected. These results
suggest that the 25 nm CE will approximate near zero-order kinet-
ics. The free aqueous diffusion coefﬁcient of Avastin was esti-
mated to be 6.6  107 cm2/s using the diffusion coefﬁcient of
BSA, viscosity of water at 20 C and 37 C, and Avastin and BSA
molecular weights (see Eq. (1)). The diffusion coefﬁcients for thick-
ness of 100 lm for each PP 100 nm, CE 100 nm and CE 25 nm are
1.18  108, 1.74  109, and 0.99  109 cm2/s, respectively.
3.4. Drug release experiments
Different Avastin and PVA concentrations were tested in the
CDR for dissolution rates. Fig. 4 represents cumulative amount of
Avastin in micrograms in the 50 mg/ml PVA solution. Both 75
and 50 mg/ml PVA were tested, however the 50 mg/ml concentra-
tion was easier to handle and inject into the CDRs. As shown in
Fig. 5, linear delivery curve (approaching zero-order kinetics) was
achieved after 2 days with estimated rate of diffusion of 0.06–
0.08 mg/day (which is less than the standard monthly dose of
Avastin of 2.5 mg/month but still in effective range).
3.5. Accelerated stability testing for (Avastin + PVA)
The accelerated stability testing in our study depends mainly on
change of activity of Avastin and not any physical changes.
According to our preliminary data in Fig. 6, the reaction rate (K)
at 37 C was found to be 0.00166 day1. Further experiments are
required at more temperature points and to compare the Ava-
stin + PVA formula with Avastin only.4. Discussion
A circular prototype of the capsule drug ring was developed to
maximize the volume available in the capsular bag with a reservoirvolume of approximately 50 ll. This device is a novel idea for treat-
ment of anterior and posterior chronic eye diseases. It is the ﬁrst to
use the capsular bag as a medium for drug delivery. The CDR re-
ported here consists of (i) drug reservoir shell; (ii) semi-permeable
hydrophilic membrane for continuous and controlled drug elution;
and (iii) two silicone membrane check valves for reﬁlls as shown in
Fig. 2. Polyvinyl alcohol (PVA) was used as the polymer carrier to
enhance controlled release and stability of the drug, Avastin.
We successfully demonstrated feasibility of fabrication, structural
integrity and bonding of the semi-permeable membrane to the
shell, valve competency, near zero-order kinetics of release, and
drug stability within a polymer matrix.
Multiple valves are provided to permit multiple drug chambers
to ensure versatility of the device for multiple ocular diseases. The
CDR shell has two eyelets at the open ends to allow for rotation and
manipulation in the lens capsule after implantation. Based on the
needs of the eye disease, the semi-permeable membrane of the
CDR could be faced either to the anterior chamber or to the poster-
ior chamber for drug delivery. These two properties (multiple drug
chambers and diffusion side facing either the anterior or posterior
chamber) serve as a platform for many chronic diseases that need
multiple drugs.
The incorporation of valves in the CDR was successful ensuring
the potential for reﬁllability. Semi-permeable membranes were
also successfully bonded to the PMMA shell. The comparison be-
tween the diffusion coefﬁcients across semi-permeable mem-
branes or in free aqueous solution shows the importance of the
semi-permeable membrane for sustained drug delivery system
for the CDR device. These ﬁndings need to be conﬁrmed for obtain-
ing near zero-order kinetics up to 6 months.
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glycine and arginine) and poly alcohols have been demonstrated
to reduce the rate of protein aggregation (Baynes & Trout, 2004;
Cleland, Powell, & Shire, 1993). The presence of PVA acts both as
a stabilizer and an increasing viscosity agent for Avastin in the
CDR.
In summary, a novel non-biodegradable drug delivery device
speciﬁcally designed to be implanted in lens capsule has been
developed, fabricated and tested successfully to determine ade-
quate drug formulation with PVA carrier for near-zero order elu-
tion. Further experiments will entail implantation of the CDR in a
rabbit model (new to assess any future potential problems in hu-
mans). Long term implantation may result in the occlusion of pores
if signiﬁcant ﬁbrosis occurs. In addition, ocular zonular integrity
will be studied and monitored; however our target is to have total
mass <200 mg as human cataracts typically are 200–250 mg in
mass, which is tolerated by normal zonules. Toxicity and biocom-
patibility will be investigated, in addition to the pharmacokinetics
proﬁle of Avastin in vivo.Acknowledgments
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